Epstein Secrets

ITAL LLC EFTA_R1_01138807 EFTA02295533 The Case for Investment • Investment opportunities identified • First 4 investments are teed up • Short time & limited capital to profit/liquidity • Managing Director's hands-on involvement • Competitive fees - 2%/20% DAC..., CAPITAL Li_c EFTA_R1_01138808 EFTA02295534

and ViroPharma Incorporated. DACART CAPITAL LLC EFTA_R1_01138848 EFTA02295574 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner ■ Kevin Hrusovsky - Perkin Elmer, President of Life Sciences & Technology ■ Dan Junius - lmmunogen, CEO • Al Sommers - JHU, For

AR I C API JAL LLC7 • r EFTA00506112 The Case for Investment ■ Investment opportunities identified ■ First 4 investments are teed up • Short time & limited capital to profit/liquidity ■ Managing Director's hands-on involvement • Competitive fees - 2%/20% DACARTGAPIIAL LLC, EFTA00506113 The Case for Invest

Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506153 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner • Kevin Hrusovsky - Perkin Elmer, President of Life Sciences & Technology • Dan Junius - Immunogen, CEO • Al Sommers - JHU, For

nt. DACAR1 LLC: EFTA00506161 The Case for Investment • Investment opportunities identified • First 5 investments are ready, 3 backups • Short time & limited capital to profit/liquidity • Managing Director's hands-on involvement • Competitive fees — 2%/20% DACART CAPIIAL LLCL EFTA00506162 The Case for Invest

% returns over the course of four years. DACAR T C. API IAL LIS.; EFTA00506200 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner • Alex Barkas - Prospect, Managing Partner • Kevin Hrusovsky - Caliper Life Sciences, CEO • Dan Junius - lmmunogen, CEO • Al So